Objective: Our previous phase I clinical trial has confirmed the safety of Adenovirus carrying
Hepatocyte Growth Factor gene (Ad-HGF) by intracoronary administration for treating severe
coronary artery disease. This study was performed to evaluate the safety and efficacy of Ad-HGF by
percutaneous endocardial injection for treating post-infarct heart failure.
Methods: A total of 30 patients (15 in the experimental group and 15 in the control group) with postinfarct
heart failure who were not indicated to revascularization and had received the optimal standardized
medication therapy were included in the study. Percutaneous endocardial Ad-HGF gene
transfer was injected with a catheter-based intramyocardial delivery system in the experimental group.
Safety parameters were measured and compared between baseline and follow-ups in the experimental
group. The Mean Difference (MD) of efficacy parameters from baseline to 6-month follow-up was
measured in both groups and compared with each other.
Results: No one suffered from serious adverse events in the experimental group during the 6-month
follow-up. The experimental group revealed significant lower left ventricular end-diastolic dimension
(LVDd) (68.5 vs. 65.8 MD: -2.69±1.08, P=0.03) and higher LVEF of both echocardiograph (35.2 vs.
39.3, MD: 4.05±0.86, P=0.0005) and single photon emission computed tomography (27.7 vs. 30.6,
MD: 2.9±0.8, P=0.003) in the 6-month follow-up than that in the baseline, but the control group did
not (P>0.05). Compared to the control group, the experimental group showed significant improvement
ranges of lower LVDd (2.6 vs. -2.69, MD: -5.3±1.4, P=0.0009) and higher echocardiographic LVEF
(-2 vs. 4.05, MD: 6.1±1.6, P=0.0008) from baseline to 6-month follow-up.
Conclusion: Percutaneous endocardial administration of Ad-HGF is safe and potentially efficient in
improving LVEF and lowering LVDd of patients with post-infarct heart failure.